In addition, broader evaluation of non–AR-driven resistance mechanisms, such as the recently described Double Negative Prostate Cancer classifier, may identify a distinct population of patients with different outcomes following treatment with ARSIs. The gene discussed is AR; the disease is prostate carcinoma.